Trial "Examining Effects of Ocrevus on Cognitive Fatigue Using fMRI" Marked Completed

A clinical trial associated with glatiramer, registered as NCT04448977 and titled "Examining Effects of Ocrevus on Cognitive Fatigue Using fMRI," was listed with a status update on August 11, 2026. The trial status is recorded as completed. No phase information was provided in the available record. The study title indicates an examination of cognitive fatigue using fMRI in connection with Ocrevus. No specific results, outcomes, or efficacy data were included in this update. The completion status reflects the trial's progression stage as recorded on ClinicalTrials.gov and does not by itself indicate any particular finding. Readers should note that a completed status means the study has concluded data collection or activities as defined by the registry, not that results have been published or reviewed. Glatiramer remains an approved compound, and this update pertains specifically to the referenced trial record rather than to any new regulatory action. Further details on trial design, enrollment, or outcomes were not part of this update and are not described here. For additional context on glatiramer, including its approved uses and background, readers can consult the compound overview.